InterveXion Announces Positive Data in Phase 2 Study of Devextinetug in Patients with METH Overdose
Devextinetug safe and well-tolerated in patients presenting with methamphetamine overdose, and normalized agitation without producing...
top of page
InterveXion Therapeutics, LLC
Search
intervexion
- Jul 5, 2022
- 2 min
InterveXion Enrolls First Patient in OUTLAST, a Phase 2 Study of IXT-m200 in METH Use Disorder
- First clinical trial of an anti-METH antibody in patients seeking treatment for methamphetamine use disorder LITTLE ROCK, ARKANSAS,...
intervexion
- Apr 4, 2022
- 2 min
InterveXion to Present Positive Phase 2 STAMPOUT Study Data at Upcoming CPDD Meeting
STAMPOUT is the first positive Phase 2 proof-of-concept trial for an anti-METH antibody LITTLE ROCK, ARKANSAS, USA, April 4, 2022...
bottom of page